| 09/07/26 | 07:00:04 | 9 Jul 2026 | | Accelerated Amortized Payment of Bond Installment |
| 08/07/26 | 07:00:04 | 8 Jul 2026 | | Avacta Appoints Patrick Vink Deputy Chairman |
| 25/06/26 | 07:00:04 | 25 Jun 2026 | | Platform-Validating Data with Faridoxorubicin |
| 25/06/26 | 07:00:04 | 25 Jun 2026 | | FDA Agreement on Pivotal Trial Design for AVA6000 |
| 23/06/26 | 07:00:03 | 23 Jun 2026 | | Result of AGM |
| 22/06/26 | 07:00:08 | 22 Jun 2026 | | Year-to-date business update ahead of AGM |
| 05/06/26 | 07:00:02 | 5 Jun 2026 | | Oversubscribed Strategic Equity Fundraise of £9m |
| 01/06/26 | 15:00:00 | 1 Jun 2026 | | Block Listing - Application to AIM |
| 01/06/26 | 07:00:09 | 1 Jun 2026 | | Clinical data on AVA6000 in salivary gland cancers |
| 29/05/26 | 07:00:05 | 29 May 2026 | | Posting of Annual Report and Notice of AGM |
| 29/05/26 | 07:00:04 | 29 May 2026 | | Board Director Changes |
| 19/05/26 | 07:00:08 | 19 May 2026 | | Unaudited Preliminary Full Year 2025 Results |
| 13/05/26 | 07:00:06 | 13 May 2026 | | Notice of Preliminary Results and Presentation |
| 13/05/26 | 07:00:03 | 13 May 2026 | | Issue of Equity and Total Voting Rights |
| 06/05/26 | 07:00:04 | 6 May 2026 | | Pre|CISION® payload release vs approved ADCs |
| 28/04/26 | 07:00:11 | 28 Apr 2026 | | Block Listing Six Monthly Return |
| 21/04/26 | 07:00:06 | 21 Apr 2026 | | Avacta data AACR underline AVA6103 profile |
| 14/04/26 | 11:37:07 | 14 Apr 2026 | | Christina Coughlin - In Vivo 2026 Rising Leader |
| 09/04/26 | 07:00:05 | 9 Apr 2026 | | Q1 2026 Business Update |
| 08/04/26 | 07:00:09 | 8 Apr 2026 | | Avacta Announces Science Day 2026 |
| 31/03/26 | 07:00:10 | 31 Mar 2026 | | First patient treated in Phase 1 trial of AVA6103 |
| 27/03/26 | 07:00:04 | 27 Mar 2026 | | Result of Oversubscribed Fundraise |
| 26/03/26 | 17:16:49 | 26 Mar 2026 | | Proposed Fundraise to raise approximately £10m |
| 26/03/26 | 16:44:56 | 26 Mar 2026 | | Issue of Equity |
| 17/03/26 | 07:00:15 | 17 Mar 2026 | | Presentations of pre|CISION® Platform Candidates |
| 16/03/26 | 07:00:10 | 16 Mar 2026 | | Phase 1 study opening for AVA6103 |
| 24/02/26 | 07:00:07 | 24 Feb 2026 | | PreCISION payload delivery advantage over ADC |
| 18/02/26 | 07:00:07 | 18 Feb 2026 | | Avacta to Participate in Conference March 2026 |
| 09/02/26 | 07:00:07 | 9 Feb 2026 | | Appointment of CSO |
| 03/02/26 | 07:00:10 | 3 Feb 2026 | | Faridoxorubicin Program Clinical Updates |
| 21/01/26 | 07:00:08 | 21 Jan 2026 | | FDA Clearance of IND Application for AVA6103 |
| 20/01/26 | 07:01:00 | 20 Jan 2026 | | Year-end trading update |
| 20/01/26 | 07:00:10 | 20 Jan 2026 | | Appointment of Nominated Adviser & TVR |
| 18/12/25 | 07:00:08 | 18 Dec 2025 | | Avacta reports new AVA6103 pharmacology data |
| 17/12/25 | 07:00:09 | 17 Dec 2025 | | Faridoxorubicin Phase 1b SGC data |
| 08/12/25 | 07:00:11 | 8 Dec 2025 | | Preliminary Data in Faridoxorubicin Phase 1b Trial |
| 03/11/25 | 08:24:46 | 3 Nov 2025 | | Completion of Placing and TVR |
| 27/10/25 | 17:39:27 | 27 Oct 2025 | | Block Listing Six Monthly Return |
| 27/10/25 | 07:00:12 | 27 Oct 2025 | | Avacta presents preclinical data at AACR-NCI-EORTC |
| 23/10/25 | 17:00:00 | 23 Oct 2025 | | Notice of Investor Presentation |
| 20/10/25 | 07:01:01 | 20 Oct 2025 | | Equity fundraise of £16 million |
| 20/10/25 | 07:00:09 | 20 Oct 2025 | | Avacta Presents Phase 1a Data for Faridoxorubicin |
| 13/10/25 | 07:00:12 | 13 Oct 2025 | | Avacta to present data at EORTC-NCI-AACR |
| 30/09/25 | 07:00:11 | 30 Sept 2025 | | Interim Half Year Results 2025 |
| 15/09/25 | 07:00:13 | 15 Sept 2025 | | Notice of Interim Results |
| 09/09/25 | 07:00:17 | 9 Sept 2025 | | Shortlisted for AIM Awards Technology of the Year |
| 01/09/25 | 07:00:10 | 1 Sept 2025 | | Avacta completes sale of Coris Bioconcept |
| 29/08/25 | 07:00:09 | 29 Aug 2025 | | Amendments to Convertible Bond + equity fundraise |
| 30/07/25 | 07:00:12 | 30 Jul 2025 | | Avacta to Present at ESMO Congress |
| 28/07/25 | 07:48:16 | 28 Jul 2025 | | Agreement to Sell Coris Bioconcept SRL |
